Skip to main content
Top
Published in: Journal of General Internal Medicine 5/2008

01-05-2008 | Original Article

Variations in Practice Guideline Adherence for Abnormal Cervical Cytology in a County Healthcare System

Authors: Rita Singhal, MD, MPH, Lisa V. Rubenstein, MD, MSPH, Mingming Wang, MPH, Martin L. Lee, PhD, Anwar Raza, MD, Christine H. Holschneider, MD

Published in: Journal of General Internal Medicine | Issue 5/2008

Login to get access

Abstract

Background

Reduction in cervical cancer incidence and mortality is not only dependant on promoting cervical cancer screening but also on providing appropriate follow-up and treatment of abnormal cervical cytology.

Objectives

The objective of this study was to determine variations in guideline adherence for women requiring abnormal cervical cytology follow-up.

Subjects

Subjects of the study are women 18 years or older with an abnormal Pap test in 2000 within a large county healthcare system (n = 8,571).

Measurements

Guideline adherence was determined by the presence or absence of the appropriate follow-up procedure within an acceptable time interval for each degree of cytological abnormality. Patients with no follow-up studies were deemed to be lost to follow-up.

Results

Of study subjects, 18.5% were lost to follow-up care. Of the remaining 6,987 women, 60.3% received optimal care, 9.4% received suboptimal care, and 30.3% received poor care. Follow-up rates were higher for patients with higher degree of cytological abnormality (OR, 1.29, 95% CI, 1.17–1.42), older patients (OR, 1.03, 95% CI, 1.02–1.030) and those receiving the index Pap test at a larger healthcare facility (OR, 1.13; 95% CI, 1.01–1.27). Receiving optimal care was positively correlated with higher degree of cytological abnormality (p < .0001) and larger facility size (p = .002). Regional variations in care demonstrated the largest cluster having the lowest lost to follow-up rate and the most optimal care.

Conclusions

A significant number of women with abnormal cervical cytology are receiving less than optimal care. Further studies are required to determine the specific healthcare delivery practices that need to be targeted to improve guideline adherence for follow-up of abnormal cytology.
Literature
1.
go back to reference American Cancer Society. Cancer Facts and Figures, 2006. Atlanta, Georgia: American Cancer Society; 2006. American Cancer Society. Cancer Facts and Figures, 2006. Atlanta, Georgia: American Cancer Society; 2006.
2.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality, Total US (1969–2002). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality, Total US (1969–2002). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
3.
go back to reference Liu T, Wang X, Waterbor JW, Weiss HL, Soong SJ. Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973–1992. J Health Care Poor Underserved. 1998;9:420–32.PubMed Liu T, Wang X, Waterbor JW, Weiss HL, Soong SJ. Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973–1992. J Health Care Poor Underserved. 1998;9:420–32.PubMed
4.
go back to reference Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr. 1996:1–6. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr. 1996:1–6.
5.
go back to reference Lawson HW, Henson R, Bobo JK, Kaeser MK. Implementing recommendations for the early detection of breast and cervical cancer among low-income women. MMWR Recomm Rep. 2000;49:37–55.PubMed Lawson HW, Henson R, Bobo JK, Kaeser MK. Implementing recommendations for the early detection of breast and cervical cancer among low-income women. MMWR Recomm Rep. 2000;49:37–55.PubMed
6.
go back to reference Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national screening program, 1991–1995. Obstet Gynecol. 1998;92:745–52.PubMedCrossRef Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national screening program, 1991–1995. Obstet Gynecol. 1998;92:745–52.PubMedCrossRef
7.
go back to reference Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer. 2000;88:2398–424.PubMedCrossRef Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer. 2000;88:2398–424.PubMedCrossRef
10.
go back to reference Patient Assessment Survey. Los Angeles, CA: Los Angeles County Department of Health Services/UCLA, 1999. Patient Assessment Survey. Los Angeles, CA: Los Angeles County Department of Health Services/UCLA, 1999.
11.
go back to reference Kaplan CP, Bastani R, Belin TR, Marcus A, Nasseri K, Hu MY. Improving follow-up after an abnormal pap smear: results from a quasi-experimental intervention study. J Womens Health Gend Based Med. 2000;9:779–90.PubMedCrossRef Kaplan CP, Bastani R, Belin TR, Marcus A, Nasseri K, Hu MY. Improving follow-up after an abnormal pap smear: results from a quasi-experimental intervention study. J Womens Health Gend Based Med. 2000;9:779–90.PubMedCrossRef
12.
go back to reference Marcus AC, Crane LA, Kaplan CP, et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care. 1992;30:216–30.PubMedCrossRef Marcus AC, Crane LA, Kaplan CP, et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care. 1992;30:216–30.PubMedCrossRef
13.
go back to reference Marcus AC, Kaplan CP, Crane LA, et al. Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care. 1998;36:397–410.PubMedCrossRef Marcus AC, Kaplan CP, Crane LA, et al. Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care. 1998;36:397–410.PubMedCrossRef
14.
go back to reference Michielutte R, Diseker RA, Young LD, May WJ. Noncompliance in screening follow-up among family planning clinic patients with cervical dysplasia. Prev Med. 1985;14:248–58.PubMedCrossRef Michielutte R, Diseker RA, Young LD, May WJ. Noncompliance in screening follow-up among family planning clinic patients with cervical dysplasia. Prev Med. 1985;14:248–58.PubMedCrossRef
15.
go back to reference Benard VB, Lee NC, Piper M, Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991–1998 (United States). Cancer Causes Control. 2001;12:61–8.PubMedCrossRef Benard VB, Lee NC, Piper M, Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991–1998 (United States). Cancer Causes Control. 2001;12:61–8.PubMedCrossRef
16.
go back to reference Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–9.PubMedCrossRef Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–9.PubMedCrossRef
17.
go back to reference Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866–9.PubMedCrossRef Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866–9.PubMedCrossRef
18.
go back to reference Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.PubMedCrossRef Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.PubMedCrossRef
20.
go back to reference Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105:501–6.PubMed Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105:501–6.PubMed
21.
go back to reference Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol. 2003;102:259–65.PubMedCrossRef Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol. 2003;102:259–65.PubMedCrossRef
22.
go back to reference Smith-McCune K, Mancuso V, Contant T, Jackson R. Management of women with atypical Papanicolaou tests of undetermined significance by board-certified gynecologists: discrepancies with published guidelines. Am J Obstet Gynecol. 2001;185:551–6.PubMedCrossRef Smith-McCune K, Mancuso V, Contant T, Jackson R. Management of women with atypical Papanicolaou tests of undetermined significance by board-certified gynecologists: discrepancies with published guidelines. Am J Obstet Gynecol. 2001;185:551–6.PubMedCrossRef
23.
go back to reference Schnatz PF, Guile M, O’Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006;107:701–8.PubMed Schnatz PF, Guile M, O’Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006;107:701–8.PubMed
24.
go back to reference Adams AL, Gidley J, Roberson J, Wang W, Eltoum I, Chhieng DC. Clinical significance of unsatisfactory conventional pap smears owing to inadequate squamous cellularity defined by the Bethesda 2001 criterion. Am J Clin Pathol. 2005;123:738–43.PubMedCrossRef Adams AL, Gidley J, Roberson J, Wang W, Eltoum I, Chhieng DC. Clinical significance of unsatisfactory conventional pap smears owing to inadequate squamous cellularity defined by the Bethesda 2001 criterion. Am J Clin Pathol. 2005;123:738–43.PubMedCrossRef
25.
go back to reference Fidda N, Miron J, Rodgers WH, Rader A. Impact of the new Bethesda System 2001 on specimen adequacy of conventional cervicovaginal smears. Diagn Cytopathol. 2004;30:235–9.PubMedCrossRef Fidda N, Miron J, Rodgers WH, Rader A. Impact of the new Bethesda System 2001 on specimen adequacy of conventional cervicovaginal smears. Diagn Cytopathol. 2004;30:235–9.PubMedCrossRef
26.
go back to reference Montz FJ, Monk BJ, Fowler JM, Nguyen L. Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol. 1992;80:385–8.PubMed Montz FJ, Monk BJ, Fowler JM, Nguyen L. Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol. 1992;80:385–8.PubMed
27.
go back to reference The ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393–400. The ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393–400.
28.
go back to reference Kaplan CP, Bastani R, Marcus A, Breslow L, Nasseri K, Chen L. Low income women with cervical abnormalities: Individual and system factors affecting follow-up. J Women’s Health. 1995;4:179–88.CrossRef Kaplan CP, Bastani R, Marcus A, Breslow L, Nasseri K, Chen L. Low income women with cervical abnormalities: Individual and system factors affecting follow-up. J Women’s Health. 1995;4:179–88.CrossRef
29.
go back to reference Benard VB, Lawson HW, Eheman CR, Anderson CR, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105:1323–8.PubMed Benard VB, Lawson HW, Eheman CR, Anderson CR, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105:1323–8.PubMed
Metadata
Title
Variations in Practice Guideline Adherence for Abnormal Cervical Cytology in a County Healthcare System
Authors
Rita Singhal, MD, MPH
Lisa V. Rubenstein, MD, MSPH
Mingming Wang, MPH
Martin L. Lee, PhD
Anwar Raza, MD
Christine H. Holschneider, MD
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 5/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0528-x

Other articles of this Issue 5/2008

Journal of General Internal Medicine 5/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.